data + articles · 2 listed
newest 2026spec sheet10 rows
NM-2-AI is the N-methyl version of 2-aminoindane, the same ring-locked amphetamine analog with a methyl group added to the nitrogen. Being an aminoindane analog of 2-AI, it is presumed to share its monoamine-releasing mechanism, acting mainly on norepinephrine with weaker dopamine involvement. It is an obscure research chemical stimulant with limited human data.
- Alertness and energy
- Appetite suppression
- Stimulant headspace
- Raised blood pressure and heart rate
- Insomnia and anxiety
- Cardiovascular strain
- Poorly defined safety margins
Mechanism
As an N-methylated aminoindane it is presumed to work like 2-AI, releasing and inhibiting reuptake of and, more weakly, (it acts on the transporter proteins for these neurotransmitters). The added N-methyl group commonly shifts an amine's potency and duration, much as methamphetamine differs from amphetamine, though the exact profile in humans is not well established. Its rigid indane ring keeps it in the noradrenergic-leaning stimulant family.
receptor fingerprint
transporter (NET)Presumed releasing agent / reuptake inhibitor
()Presumed releasing agent / reuptake inhibitor
Safetyrisks and cautions, not medical advice
Because it is a stimulant that pushes norepinephrine, expect raised blood pressure and heart rate, insomnia, and anxiety, along with cardiovascular strain. There is almost no human safety data, so its margins should be treated as unknown and conservatively. Combining it with MAOIs, other stimulants, or serotonergic drugs raises cardiovascular and serotonergic risk. Not medical advice.
Subjective profileweighing the evidence above
Not worth it. The mechanism is inferred rather than measured, there is essentially no human data, and it offers nothing a well-characterized stimulant does not while carrying the same blood pressure and cardiovascular load with margins nobody has mapped. There is no reason to be the person who finds out.
Resources
This entry is here for reference.
Research
- 1.Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives
- 2.First toxicity profile of aminoindane-based new psychoactive substances: 2-aminoindane (2-AI, CAS: 2975-41-9) and N-Methyl-2-aminoindane (NM-2-AI, CAS: 24445-44-1) - comprehensive prediction of toxicological endpoints important from clinical and forensic perspective using in silico multi-approach
2 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
How does NM-2-AI relate to 2-AI?
It is 2-aminoindane with a methyl group added to the nitrogen, presumed to share the same noradrenergic-leaning release mechanism.
Is much known about it?
No. It is an obscure research chemical with very little human data, so its effects and risks are described conservatively.
Is it a psychedelic or entactogen?
No, it is a stimulant; despite its indane ring it is not a serotonin-releasing entactogen like some other aminoindanes.
Adverse effects
- Raised blood pressure and heart rate
- Insomnia and anxiety
- Cardiovascular strain
- Poorly defined safety margins